Summary & Overview
HCPCS G9209: Hepatitis C Quantitative RNA Testing 4–12 Weeks After Treatment Start
HCPCS Level II code G9209 represents quantitative hepatitis C virus (HCV) RNA testing documented as performed between 4 and 12 weeks after starting antiviral treatment. This early on-treatment viral load measurement is a key clinical benchmark to evaluate initial virologic response and inform subsequent management decisions. Nationally, use of a specific HCPCS Level II code for this interval supports standardized reporting and tracking of on-treatment HCV monitoring across care settings.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines typical coverage and billing practices for on-treatment HCV RNA monitoring under these major payers and highlights areas where policy language and documentation requirements most commonly affect claims processing.
Readers will find an overview of the clinical context for timing of testing after treatment initiation, the service setting and coding considerations, and what to expect in payer interactions. The piece summarizes common documentation expectations, typical sites of service for specimen collection and testing, and benchmarks that payers and programs use when evaluating medical necessity for on-treatment HCV RNA testing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9209 documents hepatitis C quantitative RNA testing performed between 4 and 12 weeks after initiation of antiviral treatment. The code indicates measurement of viral load to assess early virologic response during hepatitis C therapy.
Service Type: Laboratory diagnostic test — quantitative hepatitis C RNA (viral load) monitoring
Typical Site of Service: Clinical laboratory or outpatient clinic drawing site where blood specimens are collected and processed for molecular testing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with chronic hepatitis C virus infection begins direct-acting antiviral (DAA) therapy. The clinician documents baseline HCV RNA quantitative testing prior to initiation and schedules follow-up viral load testing between 4 and 12 weeks after therapy start to assess early virologic response and treatment adherence. The specimen is collected at an outpatient laboratory associated with the hepatology clinic or at a community phlebotomy site. The laboratory performs a quantitative HCV RNA PCR assay and returns a numeric viral load. Results are reviewed by the prescribing hepatologist or infectious disease specialist to confirm virologic suppression, guide ongoing monitoring, and support decisions about treatment duration or need for adherence counseling. Typical workflow steps: order placed by provider; patient presents to clinic or lab for phlebotomy; sample processed by molecular laboratory; result reported in the electronic health record; clinician documents interpretation and any follow-up actions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit for assessment is performed and clearly documented on the same date as specimen collection or counseling related to HCV therapy. |
26 | Professional component | Use when billing only the professional component of a split technical/professional laboratory service (rare for molecular tests billed as global).